Bakris G L
Rush University Hypertension Center, Rush Presbyterian/St. Luke's Medical Center, Chicago, IL, USA.
Diabetes Res Clin Pract. 1998 Apr;39 Suppl:S35-42. doi: 10.1016/s0168-8227(98)00019-9.
It is well accepted that a reduction of arterial pressure to levels of less than 140/90 mmHg will slow the decline in renal function among patients with diabetic nephropathy. More recently it is appreciated that the reduction of arterial pressure to levels much below 130/85 mmHg provides even greater levels of protection against the progression of renal disease. Given that the achievement of blood pressure reduction to such a level requires more than one medication and that the patient's compliance is best with a once-daily medication, it makes sense to combine antihypertensive medications so as to maximize the benefit. In this way, fixed dose combination medications yield synergistic effects on blood pressure reduction while providing, in some cases, maximal benefit to preservation of renal function. Such a combination is the verapamil/trandolapril combination. This paper discusses in great detail the advantages of blood pressure reduction and the types of medications that may achieve both protection against diabetic nephropathy progression as well as blood pressure reduction.
人们普遍认为,将动脉血压降至低于140/90 mmHg的水平将减缓糖尿病肾病患者肾功能的下降。最近人们认识到,将动脉血压降至远低于130/85 mmHg的水平能提供更大程度的保护,防止肾病进展。鉴于将血压降至如此水平需要不止一种药物,且患者对每日一次用药的依从性最佳,将抗高血压药物联合使用以最大化益处是合理的。通过这种方式,固定剂量复方药物在降低血压方面产生协同作用,同时在某些情况下,对保护肾功能提供最大益处。这样的一种组合就是维拉帕米/群多普利组合。本文详细讨论了降低血压的益处以及可能实现预防糖尿病肾病进展和降低血压的药物类型。